KKRC
CELU icon

Kohlberg Kravis Roberts & Co’s Celularity CELU Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,944
Closed -$1.3M – 144
2021
Q1 		$1.3M Buy
+12,944
New +$1.33M 0.01% 63

Other funds holding CELU

WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's CELU Position: Q2 2021 in Review

Kohlberg Kravis Roberts & Co sold out of Celularity (CELU) in Q2 2021, closing a stake of 12,944 shares — an estimated $1.3M sold.

Kohlberg Kravis Roberts & Co first reported a position in CELU in Q1 2021 and held it in 1 quarter. The position peaked at $1.3M in Q1 2021. 33 funds tracked by Wall St. Rank hold CELU as of Q2 2021.

  • Kohlberg Kravis Roberts & Co reported no remaining Celularity position as of Q2 2021 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 12,944 Celularity shares in Q2 2021, an estimated $1.3M.
  • Kohlberg Kravis Roberts & Co first reported a position in Celularity in Q1 2021 and held it in 1 quarter.
  • Kohlberg Kravis Roberts & Co's Celularity position peaked at $1.3M in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Celularity as of Q2 2021.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q2 2021, filed 16 Aug 2021.